Vitamin D receptor exhibits different pharmacodynamic features in tumoral and normal microenvironments: A molecular

Sergio R Ribone1, Maria J Ferronato2, Cristian Vitale3

  • 1Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba. X5000HUA, Córdoba, Argentina.

Insights

New vitamin D receptor (VDR) agonists show promise for cancer treatment by selectively targeting tumor cells. Molecular modeling revealed specific histidine residue properties in VDR that enable this selectivity, paving the way for improved cancer therapies.

Area of Science:

  • Computational chemistry and structural biology
  • Molecular pharmacology and drug discovery

Background:

  • The vitamin D receptor (VDR) is a therapeutic target for cancer treatment.
  • The VDR agonist calcitriol has limited clinical use due to hypercalcemic side effects.
  • Novel calcitriol analogues with improved therapeutic profiles are under development.

Purpose of the Study:

  • To elucidate the atomistic basis of selectivity for novel calcitriol analogues against tumor cells.
  • To understand the role of VDR's physicochemical environment in analogue selectivity.

Main Methods:

  • Molecular modeling techniques including molecular docking, molecular dynamics, and constant pH molecular dynamics (CpHMD).
  • Free energy of binding analysis.
  • Investigation of VDR behavior in simulated tumoral (pH 6) and normal (pH 7.4) cellular environments.

Main Results:

  • Specific tautomeric configurations of histidine residues (His305 and His397) were linked to bioactivity.
  • His305 exhibited increased acidity (pKa 5.2) compared to His397 (pKa 6.8) and typical histidine.
  • Selective calcitriol analogues showed favorable interactions in the acidic tumoral VDR environment, unlike non-selective compounds.

Conclusions:

  • The differential acidity of VDR histidine residues contributes to calcitriol analogue selectivity.
  • VDR's interaction profile varies significantly between tumoral and normal cellular pH environments.
  • These findings provide a foundation for in silico screening and design of novel VDR-targeting cancer drugs.